Allarity Ends the Third Quarter With 24.1 Million Dollars in Cash: A Net Loss of 6.2 Million Dollars and Research Spending of 4.2 Million Dollars, Released November 13 With Fourth-Quarter Guidance
Allarity Therapeutics, a Phase 2 clinical-stage pharmaceutical company developing stenoparib, a dual PARP and WNT pathway inhibitor, reported financial results for the third quarter ended September 30, 2026 on November 13, 2026, and provided an update on its clinical and business activities. All figures below are from the body of the company's release, and this report offers no investment advice.
As of September 30, 2026, Allarity had 24.1 million dollars in cash and restricted cash, including 10.0 million dollars in restricted cash.
Research and development expenses were 4.2 million dollars, compared with 1.2 million dollars in the third quarter of 2025. General and administrative expenses were 1.3 million dollars, unchanged from 1.3 million dollars a year earlier. The net loss attributable to common stockholders was 6.2 million dollars, compared with 2.8 million dollars a year earlier, and a 3.2 million dollar one-time manufacturing expense accounted for most of the year-over-year increase.
The company provided guidance for earnings of 0.01 to 0.04 dollars per share in the fourth quarter, and anticipates a full year 2026 loss between 0.73 and 0.76 dollars per share. The company noted these figures are preliminary and unaudited, and actual results may differ.
Subsequent to quarter-end, in October, Allarity announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy.
Source: Allarity Therapeutics
Published by GSM · USA (original Chinese edition)
Photo: 图：美国国家卫生研究院细胞肿瘤学实验室（Allarity相关资料图）。National Institutes of Health，Public domain，Wikimedia Commons。 / Photo: 美国国家卫生研究院细胞肿瘤学实验室. National Institutes of Health, Public domain, via Wikimedia Commons.
British Insurer Aviva Reports Its Third Quarter 2026 Trading Update: General Insurance Premiums of 11.8 Billion Pounds, Up 19 Percent, a Combined Operating Ratio of 93.8 Percent and a Solvency II Cover Ratio of 179 Percent2026-11-14
Questerre Third-Quarter Production Averages 4,634 Barrels of Oil Equivalent per Day: Petroleum and Natural Gas Revenue of 50.8 Million Canadian Dollars and a Net Loss of 27.6 Million Canadian Dollars as the PX Energy Turnaround Finishes on Schedule, Released November 122026-11-14